Global DNA Vaccine Market Outlook 2022 Featuring GlaxoSmithKline’s Engerix-B, Twinrix, and Fendrix; Merck’s Gardasil, and Recombivax HB; Protein Sciences Corporation’s Flublok - ResearchAndMarkets.com

September 21, 2018

DUBLIN--(BUSINESS WIRE)--Sep 21, 2018--The “Global DNA Vaccine Market Outlook 2022” report has been added to ResearchAndMarkets.com’s offering.

Global DNA Vaccine Market Outlook 2022 provides an in-depth analysis of the global DNA Vaccines market, presenting readers a profound understanding of the various challenges, drivers, and developments in this industry. The study has publicized that though the numbers of DNA vaccines that target the human clinical segment are relatively fewer in number, however due to high sales of these vaccines, the DNA vaccine market is forecasted to show a phenomenal growth in the coming years.

The DNA vaccine in this report refers to the vaccines manufactured using recombinant DNA technology. The advent of these vaccines has revolutionized the healthcare market. These vaccines are more effective, as well as have less side-effects associated with them as compared to traditional vaccines. Various vaccines have been introduced in the market based on this technique.

Some of the major DNA vaccines include GlaxoSmithKline’s Engerix-B, Twinrix, and Fendrix; Merck’s Gardasil, and Recombivax HB; Protein Sciences Corporation’s Flublok, etc. Currently, the researchers are engaged in developing genetic vaccines for humans. Animal genetic vaccines are already present in the market. These vaccines are third generation vaccines and contain DNA that codes for specific proteins from a pathogen. This DNA is injected into host body and produces protein for which the body generates immune response.

The report also contains detailed and in-depth analysis of the segmentation of the DNA vaccines market based on types of DNA vaccines, therapeutic indication, end-users, and geography. Based on the type, the DNA vaccines market is divided into recombinant protein and genetic. Amongst the two segments, recombinant protein segment accounted for largest share in the market. This large share is attributed to the presence of high number of recombinant protein vaccines in the market.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. DNA Vaccine - An Introduction

4. Drivers & Challenges

5. DNA Vaccine Market Overview

6. DNA Vaccines Market by Geography

7. DNA Vaccine Market by Type

8. DNA Vaccines Market by End User

9. DNA Vaccines Market by Therapeutic Indication

10. Pipeline Analysis

11. Trends

12. Company Profiles

13. Recommendations

Companies Mentioned

Novartis International AG Merck & Co., Inc GlaxoSmithKline plc. Sanofi Zoetis Green Cross Corporation Inovio Pharmaceuticals, Inc., Bharat Biotech Protein Sciences Corporation Indian Immunologicals Ltd. Serum Institute of India Pvt. Ltd

For more information about this report visit https://www.researchandmarkets.com/research/wc7bzb/global_dna?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180921005271/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Vaccines



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/21/2018 09:06 AM/DISC: 09/21/2018 09:06 AM


Update hourly